Dynavax Announces Receipt of Communication from the U.S. FDA on HEPLISAVTM Hepatitis B Vaccine (Centre Daily Times) PDF Print

Dynavax Technologies Corporation (Nasdaq: DVAX) today announced receipt of communication from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on the two HEPLISAV TM Investigational New Drug (IND) Applications, for healthy adults and patients with end-stage renal disease (ESRD). In this communication, the FDA has requested additional clinical and safety information which ...

read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.